Accord Announces Voting Results of Annual Meeting
Shareholders voted in favour of all items of business put forth at the meeting as set out below. A total of 6,406,657 shares were represented at the AGM representing 74.85% of the total issued and outstanding shares.
1. Election of Directors
The following seven nominees were elected to serve as directors of the Company until the next annual meeting of shareholders or until their successors are elected or appointed:
Number of Votes
Percentage of Votes Cast
Name
For
Withheld
For
Withheld
David Beutel
6,105,873
300,599
95.31%
4.69%
Burt Feinberg
5,836,773
569,699
91.11%
8.89%
Simon Hitzig
5,798,373
608,099
90.51%
9.49%
Jean Holly
5,853,373
553,099
91.37%
8.63%
Gary Prager
5,829,873
576,599
91.00%
9.00%
David Spivak
5,813,273
593,199
90.74%
9.26%
Stephen Warden
5,836,773
569,699
91.11%
8.89%
Expand
2. Appointment of Auditors
KPMG LLP, Chartered Professional Accountants, was appointed as auditors of the Company for the fiscal year ending December 31, 2025.
For
Withheld
For
Withheld
6,391,547
15,110
99.76%
0.24%
Expand
About Accord Financial Corp.
Accord Financial is one of North America's most dynamic commercial finance companies providing fast, versatile financing solutions including asset-based lending, factoring, inventory finance, equipment finance (in Canada), trade finance and film/media finance. By leveraging our unique combination of financial strength, deep experience and independent thinking, we craft winning financial solutions for small and medium-sized businesses, simply delivered, so our clients can thrive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
37 minutes ago
- Associated Press
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)--Jul 8, 2025-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces that Raju Kucherlapati, PhD, has stepped down from his role as a member and Chair of the Board of Directors. 'Raju has been an integral part of PureTech's journey for almost two decades, and we are deeply grateful for his dedication and leadership,' said Bharatt Chowrira, PhD, JD, PureTech's Chief Executive Officer. 'On behalf of the board, I'd like to wish Raju all the best in his future endeavors.' PureTech has appointed Sharon Barber-Lui, PureTech's Audit Committee Chair, as Interim Chair of the Board of Directors. In collaboration with the Nominating Committee, Ms. Barber-Lui will lead the process to identify a new Chair of the Board of Directors and will engage with shareholders to gather input on the criteria and overall board evolution as part of the process. Robert Langer, ScD, PureTech's Co-founder and member of the board said, 'Raju is a unique individual, an amazing scientist, and a great friend and mentor to so many people in the biotech industry. It has been an honor and a privilege to serve alongside Raju for so many years at PureTech. I speak for the entire board in thanking him for his many years of dedication and his outstanding contributions.' During his tenure on the board, Dr. Kucherlapati helped guide PureTech from its startup phase into an established biotherapeutics company, which has an industry-leading track record of advancing breakthrough medicines, such as the recently FDA-approved Cobenfy™, and launching innovative Founded Entities, most recently, Seaport Therapeutics. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our intention to initiate a process to identify a new Chair of the Board of Directors, our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or source version on CONTACT: PureTech Investor Relations [email protected] KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH OTHER HEALTH SOURCE: PureTech Health plc Copyright Business Wire 2025. PUB: 07/08/2025 12:45 PM/DISC: 07/08/2025 12:46 PM
Associated Press
37 minutes ago
- Associated Press
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; 'ZyVersa'), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the 'Series A-2 Warrants') and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the 'Series A-3 Warrants,' and together with the Series A-2 Warrants, the 'Existing Warrants') at a reduced exercise price of $0.67. Gross cash proceeds were approximately $2.0 million before deducting financial advisor fees and other transaction expenses. The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes. In consideration for the immediate exercise in full of the Existing Warrants, the investor will receive new Series A-4 unregistered warrants in a private placement to purchase up to 6,124,930 shares of common stock (the 'Series A-4 Warrants' or the 'New Warrants'). The New Warrants will have an exercise price of $0.67 and will be initially exercisable on the date that stockholders approve the exercise of the New Warrants. The New Warrants will expire five years from the date of such approval. The closing of the warrant inducement transaction is expected to occur on or about July 9, 2025, subject to satisfaction of customary closing conditions. A.G.P./Alliance Global Partners acted as the exclusive financial advisor in connection with the transaction. The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act. The New Warrants, along with the common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to an accredited institutional investor. The Company has agreed to file a registration statement with the SEC covering the resale of common stock issuable upon exercise of the New Warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Zyversa Therapeutics, Inc. ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit Cautionary Statement Regarding Forward-Looking Statements Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management's intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc ('ZyVersa') uses words such as 'anticipates,' 'believes,' 'plans,' 'expects,' 'projects,' 'future,' 'intends,' 'may,' 'will,' 'should,' 'could,' 'estimates,' 'predicts,' 'potential,' 'continue,' 'guidance,' and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa's expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa's plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa's planned preclinical and clinical trials; the timing of the availability of data from ZyVersa's preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa's plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa's product candidates; ZyVersa's commercialization, marketing and manufacturing capabilities and strategy; ZyVersa's ability to protect its intellectual property position; and ZyVersa's estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law. Corporate, Media, IR Contact Karen Cashmere Chief Commercial Officer [email protected] 786-251-9641
Business Wire
42 minutes ago
- Business Wire
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces that Raju Kucherlapati, PhD, has stepped down from his role as a member and Chair of the Board of Directors. "Raju has been an integral part of PureTech's journey for almost two decades, and we are deeply grateful for his dedication and leadership,' said Bharatt Chowrira, PhD, JD, PureTech's Chief Executive Officer. 'On behalf of the board, I'd like to wish Raju all the best in his future endeavors.' PureTech has appointed Sharon Barber-Lui, PureTech's Audit Committee Chair, as Interim Chair of the Board of Directors. In collaboration with the Nominating Committee, Ms. Barber-Lui will lead the process to identify a new Chair of the Board of Directors and will engage with shareholders to gather input on the criteria and overall board evolution as part of the process. Robert Langer, ScD, PureTech's Co-founder and member of the board said, 'Raju is a unique individual, an amazing scientist, and a great friend and mentor to so many people in the biotech industry. It has been an honor and a privilege to serve alongside Raju for so many years at PureTech. I speak for the entire board in thanking him for his many years of dedication and his outstanding contributions.' During his tenure on the board, Dr. Kucherlapati helped guide PureTech from its startup phase into an established biotherapeutics company, which has an industry-leading track record of advancing breakthrough medicines, such as the recently FDA-approved Cobenfy™, and launching innovative Founded Entities, most recently, Seaport Therapeutics. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our intention to initiate a process to identify a new Chair of the Board of Directors, our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
